NCT05078931View on ClinicalTrials.gov

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
NSCLC
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles

DRUG

Lenvatinib

Lenvatinib 20mg will be administered orally daily.

Trial Locations (1)

200030

Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Shanghai Chest Hospital

OTHER